Medication errors account for the bulk of adverse events to medicines. How do they occur, how do we ensure they are reported if they do occur, and how may we prevent them?

In this opinion article, Maria Mantziri and Natália Hromníková argue how contrasting examples from pharmacovigilance’s past could point to a more proactive and vital future.

How does an economics theory apply to drug safety, and how can we use it to better manage rare, unexpected, and serious adverse drug reactions?

From software updates to complex human-machine interactions, medical devices pose safety challenges that require dedicated frameworks beyond drug vigilance.

Are you and your patient talking about the same thing when you discuss risk? Most likely not, and understanding this is key to effective risk communication.